NCT07092306View on ClinicalTrials.gov

A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2027

Conditions
Ewing's Sarcoma
Interventions
DRUG

Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT)

（NALIRI-VT，Nanoliposomal Irinotecan，Vincristine，Temozolomide）， Nanoliposomal Irinotecan：35 mg/m2/d，iv，D1，8，15， Temozolomide：100 mg/m2/d，po，D1-5， Vincristine：1.4 mg/m2/d，iv，D1，最大剂量2mg；

DRUG

Irinotecan Combined with Temozolomide and Vincristine (VIT)

（VIT，Vincristine，Irinotecan，Temozolomide） Irinotecan：50 mg/m2/d，iv，D1-5， Temozolomide：100 mg/m2/d，po，D1-5， Vincristine：1.4 mg/m2/d，iv，D1，最大剂量2mg；

All Listed Sponsors
lead

Tang Xiaodong

OTHER